The Latest in AML

HDACi, HMA combo improves survival for older AML patients

March 13, 2019

Guadecitabine may be option for certain MDS/AML patients

March 12, 2019

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML

February 25, 2019

Treosulfan may become standard in allo-HCT for AML/MDS

February 23, 2019

Eltrombopag ‘cannot be recommended’ during AML induction

February 9, 2019

Chemo for solid tumors and risk of tMDS/AML

January 4, 2019

FDA approves first treatment for BPDCN

December 26, 2018

Algorithm uncovers DS in AML patients on IDH inhibitors

December 7, 2018

Serious side effect of AML treatment going unnoticed, FDA warns

November 30, 2018

FDA approves gilteritinib for relapsed/refractory AML

November 29, 2018

FDA grants priority review to quizartinib

November 27, 2018

FDA approves venetoclax for AML

November 21, 2018

FDA approves glasdegib for AML

November 21, 2018

FDA approves generic drugs for APL

November 16, 2018

AP-1 plays key role in various AML subtypes, team says

November 13, 2018